348 related articles for article (PubMed ID: 27197278)
1. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.
Kelly RS; Vander Heiden MG; Giovannucci E; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):887-906. PubMed ID: 27197278
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
Lucarelli G; Rutigliano M; Galleggiante V; Giglio A; Palazzo S; Ferro M; Simone C; Bettocchi C; Battaglia M; Ditonno P
Expert Rev Mol Diagn; 2015; 15(9):1211-24. PubMed ID: 26174441
[TBL] [Abstract][Full Text] [Related]
3. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma.
Jung K; Reszka R; Kamlage B; Bethan B; Stephan C; Lein M; Kristiansen G
Int J Cancer; 2013 Dec; 133(12):2914-24. PubMed ID: 23737455
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic signatures of aggressive prostate cancer.
McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
[TBL] [Abstract][Full Text] [Related]
5. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate cancer tissue metabolomics: would clinics utilise it for diagnosis?
Bansal N; Kumar M; Sankhwar SN; Gupta A
Expert Rev Mol Med; 2023 Aug; 25():e26. PubMed ID: 37548191
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics approaches and applications in prostate cancer research.
Zhang A; Yan G; Han Y; Wang X
Appl Biochem Biotechnol; 2014 Sep; 174(1):6-12. PubMed ID: 24838846
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
9. [The role of PSA in diagnosis of prostate cancer and its recurrence].
Vergho DC; Heine K; Wolff JM
Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
[TBL] [Abstract][Full Text] [Related]
10. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.
Kumar D; Gupta A; Nath K
Expert Rev Mol Diagn; 2016 Jun; 16(6):651-61. PubMed ID: 26959614
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.
Salciccia S; Capriotti AL; Laganà A; Fais S; Logozzi M; De Berardinis E; Busetto GM; Di Pierro GB; Ricciuti GP; Del Giudice F; Sciarra A; Carroll PR; Cooperberg MR; Sciarra B; Maggi M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922033
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
Ohori M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
[TBL] [Abstract][Full Text] [Related]
13. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
Bickers B; Aukim-Hastie C
Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
[TBL] [Abstract][Full Text] [Related]
14. Application of metabolomics to prostate cancer.
Trock BJ
Urol Oncol; 2011; 29(5):572-81. PubMed ID: 21930089
[TBL] [Abstract][Full Text] [Related]
15. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.
Hansen AF; Sandsmark E; Rye MB; Wright AJ; Bertilsson H; Richardsen E; Viset T; Bofin AM; Angelsen A; Selnæs KM; Bathen TF; Tessem MB
Oncotarget; 2016 Jul; 7(27):42071-42085. PubMed ID: 27276682
[TBL] [Abstract][Full Text] [Related]
16. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in localized prostate cancer.
Ferro M; Buonerba C; Terracciano D; Lucarelli G; Cosimato V; Bottero D; Deliu VM; Ditonno P; Perdonà S; Autorino R; Coman I; De Placido S; Di Lorenzo G; De Cobelli O
Future Oncol; 2016 Feb; 12(3):399-411. PubMed ID: 26768791
[TBL] [Abstract][Full Text] [Related]
18. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
19. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
